EXACT Sciences Corporation
$ 103.39
-0.04%
23 Feb - close price
- Market Cap 19,735,931,000 USD
- Current Price $ 103.39
- High / Low $ 103.65 / 103.37
- Stock P/E N/A
- Book Value 12.58
- EPS -1.10
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.02 %
- ROE -0.09 %
- 52 Week High 103.65
- 52 Week Low 38.81
About
Exact Sciences Corporation offers cancer screening and diagnostic test products in the United States and internationally. The company is headquartered in Madison, Wisconsin.
Analyst Target Price
$105.81
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-13 | 2025-11-03 | 2025-08-06 | 2025-05-06 | 2025-02-19 | 2024-11-05 | 2024-07-31 | 2024-05-08 | 2024-02-21 | 2023-11-01 | 2023-08-01 | 2023-05-09 |
| Reported EPS | -0.21 | 0.24 | -0.01 | -0.358 | -0.2404 | -0.21 | -0.06 | -0.54 | -0.43 | -0.32 | -0.35 | -0.35 |
| Estimated EPS | 0.08 | 0.16 | -0.13 | -0.47 | -0.3327 | -0.21 | -0.24 | -0.41 | -0.36 | -0.43 | -0.41 | -0.66 |
| Surprise | -0.29 | 0.08 | 0.12 | 0.112 | 0.0923 | 0 | 0.18 | -0.13 | -0.07 | 0.11 | 0.06 | 0.31 |
| Surprise Percentage | -362.5% | 50% | 92.3077% | 23.8298% | 27.7427% | 0% | 75% | -31.7073% | -19.4444% | 25.5814% | 14.6341% | 46.9697% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0.02 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EXAS
2026-02-23 15:08:45
Exact Sciences Corporation (EXAS) has hit a new 52-week high of $103.55, bringing its market capitalization to $19.74 billion after a 118% surge over the last six months and 101.85% over the past year. Despite this growth, InvestingPro analysis suggests the stock is currently overvalued. The company's recent merger approval with Abbott Laboratories and new federal legislation for multi-cancer early detection tests are key drivers behind its performance, although some analysts have downgraded the stock to Neutral or Hold.
2026-02-23 00:44:37
The Cologuard multitarget stool DNA (mt-sDNA) test has shown high specificity in screening for colorectal cancer (CRC) among average-risk patients aged 45 to 49 years, offering a noninvasive option. Results published in Cancer Prevention Research indicate a specificity of 95.2% for nonadvanced adenomas and 96.3% for negative colonoscopic findings in this age group. This data supports Cologuard's role as a first-line screening method, particularly following recent guideline changes recommending CRC screenings begin at age 45.
2026-02-21 03:43:19
Exact Sciences Corp. shareholders have approved the proposed merger with Abbott Laboratories, making Exact Sciences a wholly-owned subsidiary of Abbott. The merger agreement passed with significant shareholder support, although the advisory vote on executive compensation was not approved. The completion of the merger is pending regulatory approvals and other customary closing conditions.
2026-02-20 21:05:04
Exact Sciences Corporation stockholders have approved the proposed acquisition by Abbott, with over 99% of votes cast in favor of the transaction. The acquisition is expected to close before the end of the second calendar quarter of 2026, granting Exact Sciences stockholders $105.00 in cash per share. Exact Sciences is a leading provider of cancer screening and diagnostic tests, including Cologuard® and Oncotype DX®.
2026-02-20 05:27:18
Exact Sciences Corp., known for its Cologuard at-home colon cancer test, is gaining significant attention due to new data, analyst calls, and increased momentum in cancer testing. The company is exploring blood-based cancer tests and oncology genomics, positioning itself as a key player in early cancer detection in the US. While offering substantial benefits like at-home convenience and broad insurance coverage, the company also faces challenges including competition, high R&D costs, and stock volatility.
2026-02-20 04:57:57
Exact Sciences Corp., known for its Cologuard at-home colon cancer test, is gaining significant attention due to new data, analyst calls, and momentum in cancer diagnostics. The US-focused company is expanding its portfolio into blood-based cancer tests and oncology genomics, aiming to make early detection more accessible. While offering substantial benefits for patients and long-term growth potential for investors, the stock faces volatility from competition, R&D costs, and reimbursement pressures.
